eli lilly glp-1 advantage decreasing Lilly's portfolio gains ground on Novo Nordisk A second helping of weight-loss

People with a personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia type 2, pancreatitis, or severe gastrointestinal conditions should avoid GLP1 weight-loss drugs unless specifically advised by their physician

These illegal operations often use deceptive marketing, making bold claims about their product while selling something that could be useless or dangerous

Know what to discuss if you miss a dose Specific instructions should always come from your prescribing clinician and your medication's guidance

GLP-1s reduce the urge to graze throughout the day, making portion control natural instead of forced

Due to which patients even stop taking their medication entirely at times